tbuckley/cabot-search huggingface dataset:
Incidence of inflammatory bowel disease in patients with ankylosing spondylitis
Authors: Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
Journal: Annals of the Rheumatic Diseases (2019)

Incidence of inflammatory bowel disease in patients with ankylosing spondylitisAnkylosing spondylitis is a long-term inflammatory disease that always affects the spine joints.The association between ankylosing spondylitis and other diseases has been extensively assessed. 1 2Recently a cohort study conducted by Schreiber et al published in Annals of the Rheumatic Diseases found that the new-onset cases of inflammatory bowel disease were uncommon in patients with ankylosing spondylitis on secukinumab therapy (1.13%, 9/794). 3n order to examine the association between ankylosing spondylitis and inflammatory bowel disease in a different country, a preliminary cohort study was undertaken using the 2005-2012 database of the Taiwan National Health Insurance Programme with 23 million residents living in Taiwan.4 Subjects ages 20-84 with a new diagnosis of ankylosing spondylitis were identified as the ankylosing spondylitis group (International Classification of Diseases, Ninth Revision code (ICD-9 code 720.0)).For every subject with ankylosing spondylitis, four sex-matched and age-matched subjects who did not have a diagnosis of ankylosing spondylitis were assigned as the non-ankylosing spondylitis group.The main outcome was a new diagnosis of inflammatory bowel disease (ICD-9 code 555-556).Table 1 presents that the overall incidence of inflammatory bowel disease was lower in the ankylosing spondylitis group than in the non-ankylosing spondylitis group, but without reaching statistical significance (1.41 vs 1.79 per 1000 person-years, incidence rate ratio 0.79, 95% CI 0.48 to 1.28; p=0.332).As stratified by sex and age, there was no statistical significance in the incidence of inflammatory bowel disease between the ankylosing spondylitis group than the non-ankylosing spondylitis group.Some caveats are discussed. Pevious studies found that the prevalence of ankylosing spondylitis in patients with inflammatory bowel disease was around 3.7%-4.5%. 5 6 One review found that the prevalence of inflammatory bowel disease in patients with ankylosing spondylitis was around 6%-14%.7 Due to both conditions likely occurring concomitantly, some researchers suggest that ankylosing spondylitis and inflammatory bowel disease might share a similar pathogenesis.8 Therefore, ankylosing spondylitis and inflammatory bowel disease might develop in the same patient, but both conditions do not have a causal relationship, which is partially confirmed by our present study.Physicians who participate in care of patients with ankylosing spondylitis should take into consideration the possibility of inflammatory bowel disease, and vice versa.
Granzyme B Expression in T-Regulatory Cells Is a Strong Predictor of Acute Graft-Versus-Host Disease after Day +30 in Patients with "Classic" Immunosuppression after Allo-HSCT
Authors: Mikhail Yu. Drokov, Elena N. Parovichnikova, Julia Davydova, Larisa A. Kuzmina, Irina V Galtseva, Nikolay M Kapranov, Vera Vasilieva, Darya Dubnyak, Olga Koroleva, Ekaterina Mikhalcova, Natalia Popova, Valery G Savchenko
Journal: Blood (2016)
Continuous Improvement of Bone Mineral Density Two Years Post Zoledronic Acid Discontinuation in Patients with Thalassemia-Induced Osteoporosis: Long-Term Follow-Up of a Randomized, Placebo-Controlled Trial.
Authors: Ersi Voskaridou, Dimitrios Christoulas, Marialena Konstantinidou, Evangelos Tsiftsakis, Eugenia Spyropoulou, Panagiotis Alexakos, Evangelos Terpos
Journal: Blood (2007)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
Authors: Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller, Martin Schreder, Christoph Tinchon, Michael Pfeilstöcker, Susanne Steinkirchner, Thomas Melchardt, Martina Mitrovic, Michael Girschikofsky, Alois Lang, Peter Krippl, Alexander Egle, Thamer Sliwa, Werner Linkesch, Michael A. Fridrik, Richard Greil
Journal: Blood (2011)
<i>Notes from the Field:</i> Environmental Contamination from E-cigarette, Cigarette, Cigar, and Cannabis Products at 12 High Schools — San Francisco Bay Area, 2018–2019
Authors: Jeremiah Mock, Yogi H. Hendlin
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

The United States is experiencing an epidemic of lung injury associated with youth electronic cigarette (e-cigarette) use, or vaping (1); in 2018, 20.8% of U.S. high school students reported currently using e-cigarettes (1).E-cigarette products such as Juul, a popular device that delivers nicotine and flavors,* are used by students at schools, including in classrooms and bathrooms.† Use of flavored e-cigarettes by youths has become an increasing concern (2).A recent analysis of the National Youth Tobacco Survey showed that among high school students who currently used e-cigarettes, the percentage who used flavored e-cigarettes increased from 65.1% in 2014 to 67.8% in 2018 (3).In 2018, 8.1% of high school students currently smoked cigarettes, and 45.7% of those students smoked menthol cigarettes.In addition, 7.6% of high school students currently smoked cigarillos, little cigars, or cigars, 43.6% of whom used flavored varieties of these products (1,3).Many youths also use cigars to make marijuana blunts (i.e., cigarillos with the tobacco removed and replaced with marijuana) (4), and some use manufactured disposable cannabis products (e.g., vape pens, vaporizer cartridges, oils, and concentrates) (5).Waste from e-cigarette products can contain plastics, nicotine, heavy metals, other chemical toxins, and hazardous lithium-ion batteries (6,7).The toxicity of combustible tobacco product waste from cigarettes (e.g., plastic cellulose acetate, nicotine, formaldehyde, lead, and cadmium) is well established (8).Cannabis product waste can include plastics, metals, electronic components, and batteries.A garbology § study of environmental contamination from e-cigarette product waste, combustible tobacco product waste, and cannabis product waste was conducted using a purposively selected, nonrandom sample of 12 public high schools with a total enrollment of 18,831 students in Alameda, Contra Costa, Marin, and San Francisco counties in California.Using 2016 data from the National Center for Education Statistics, researchers stratified schools by the percentages of students * Menthol is one of the types of tobacco-product flavoring.https://www.tobaccofreekids.org/assets/factsheets/0394.pdf.† https://truthinitiative.org/research-resources/emerging-tobacco-products/ nearly-1-5-youth-say-they-have-seen-juul-used-school.
RNA-Seq De Novo Assembly of Clonal Immunoglobulin Rearrangements Identifies Interesting Biology and Uncovers Prognostic Features in Multiple Myeloma
Authors: David Mosen-Ansorena, Rachael Bashford-Rogers, Niccolo Bolli, Stephane Minvielle, Florence Magrangeas, Kenneth C Anderson, Herve Avet-Loiseau, Giovanni Parmigiani, Nikhil C Munshi
Journal: Blood (2016)
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.
Authors: Shaji Kumar, Joan Blade, John Crowley, Harmut Goldschmidt, Antje Hoering, Sundar Jagannath, Juan José Lahuerta, Jacob Laubach, Philippe Moreau, Gareth Morgan, Robert Z. Orlowski, Antonio Palumbo, Paul Richardson, Jesús F. San Miguel, Orhan Sezer, David Siegel, Pieter Sonneveld, Jackie Szymonifka, S.Vincent Rajkumar, Brian G M Durie
Journal: Blood (2009)
ZAP-70 Expression in Chronic Lymphocytic Leukemia: Correlation with Clinical and Biological Features.
Authors: Ilaria Del Giudice, Nnenna Osuji, Estella Matutes, Alison Morilla, Ricardo Morilla, Anna Burford, Sonia Maravelaki, Kwasi Owusu-Ankomah, John Swansbury, Vasantha Brito-Babapulle, Daniel Catovsky
Journal: Blood (2004)
Novel Synthetic Histone Deacetylase Inhibitor (SK-7041) Potently Inhibits Proliferation in Acute Myeloid Leukemia Cell Lines.
Authors: Young-Ju Kim, Susan Guo, Ju Won Park, Eun Kyung Bae, Kwang-Sung Ahn, Inho Kim, Jong-Seok Lee, Young Yiul Lee, Seonyang Park, Byoung Kook Kim, Sung-Soo Yoon
Journal: Blood (2005)
T Cell Chimerism After T Cell Depleted Allogeneic Stem Cell Transplantation Is Influenced by Immunological Factors Including the Conditioning Regimen, CMV Serostatus and GvHD and Does Significantly Bias Overall Chimerism Status
Authors: Jessica C. Harskamp, Pim L.J. van der Heiden, Esther H.M. van Egmond, Sabrina A.J. Veld, Hans L. Vos, Constantijn J.M. Halkes, J.H. Frederik Falkenburg, Erik W.A. Marijt
Journal: Blood (2010)
Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial
Authors: Tashi Dorje, Gang Zhao, Khandro Tso, Jing Wang, Yaolin Chen, Lhamo Tsokey, B-K Tan, Anna Scheer, Angela Jacques, Zhixing Li, Ruochen Wang, Clara K Chow, Junbo Ge, Andrew Maiorana
Journal: The Lancet Digital Health (2019)

Coronary heart disease is rapidly increasing in developing countries, but access to cardiac rehabilitation and secondary prevention remains low. In this study, we aimed to assess the effectiveness of a smartphone-based cardiac rehabilitation and secondary prevention programme delivered via the social media platform WeChat (SMART-CR/SP).In this parallel-group, single-blind, randomised controlled trial, we recruited patients aged 18 years or older with coronary heart disease who had received percutaneous coronary interventions from a large tertiary hospital in Shanghai, China. Participants were randomly assigned (1:1) by block randomisation to either a 2-month intensive programme followed by a 4-month step-down phase of SMART-CR/SP or to usual care. In the SMART-CR/SP group, participants received comprehensive cardiac rehabilitation and secondary prevention via WeChat. The usual care group received standard outpatient cardiology follow-up but without formal cardiac rehabilitation and secondary prevention. Assessments were done at baseline, 2 months, 6 months, and 12 months. The primary outcome was change in functional capacity from baseline, measured by 6-min walk distance, at 2 months and 6 months. Analysis was by intention to treat. Research personnel involved in assessments were blinded to group allocation. Adverse-event analysis was based on percentage of patients who discontinued the study owing to adverse events. SMART-CR/SP programme-related safety issues were also recorded. This study was registered with the Chinese Clinical Trial Registry, number ChiCTR-INR-16009598.Between Nov 17, 2016, and March 18, 2017, 312 patients (mean age 60·5 years [SD 9·2]), of whom 58 (19%) were female and 254 (81%) were male, were recruited and subsequently randomly assigned to SMART-CR/SP (n=156) or usual care (n=156). The improvement in 6-min walk distance at 2 months was significantly greater in the SMART-CR/SP group (from 489·2 m [99·4] at baseline to 539·1 m [68·0]) than in the control group (from 485·0 m [93·5] at baseline to 517·8 m [74.6]), with an adjusted mean difference of 20·64 m (95% CI 7·50-33·77; p=0·034). This improvement was maintained at 6 months (mean 6-min walk distance 543·4 m [67·5] in the SMART-CR/SP group vs 523·5 m [60·2] in the control group), with a mean between-group difference of 22·29 m (8·19-36·38; p=0·027). No adverse events or SMART-CR/SP programme-related safety issues were reported by participants during the study.SMART-CR/SP was found to be a cardiac rehabilitation and secondary prevention service model with high efficacy and accessibility and to be easy to use. These results justify the implementation of similar models of care on a broader scale.Curtin University.
Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma
Authors: Anas Younes, Jesus G. Berdeja, Manish R. Patel, Kevin R. Kelly, Ian W. Flinn, John F Gerecitano, Sattva S. Neelapu, Amanda R. Copeland, Amy Akins, Myles Clancy, Anna Ma, Kaiming Sun, Ze Tian, Jing Wang, Jaye Viner, Yasuhiro Oki
Journal: Blood (2015)
Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.
Authors: Monica Bessler, Hubert Schrezenmeier, Jaroslaw P. Maciejewski, Anita Hill, Scott A. Rollins, Neal S. Young, Lucio Luzzatto
Journal: Blood (2007)
Comprehensive Structured Transition Program with Dedicated Transition Navigator Reduced Lost to Follow-up and Improved Medication Adherence in Sickle Cell Disease and Thalassemia Adolescents and Young Adults
Authors: Brooke Allemang, Kate Allan, Colleen Johnson, Melina Cheong, Patrina Cheung, Isaac Odame, Richard Ward, Suzan Williams, Kevin H.M. Kuo
Journal: Blood (2016)
Relative adrenal insufficiency post-discontinuation of topical steroids in a patient with acute lymphoblastic leukemia
Authors: Sakiko Uho, Hideaki Goto, Ako Higashime, Koji Kawaguchi, Yoko Ishikawa, Taiji Koyama, Keiji Kurata, Yoshiharu Miyata, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami
Journal: Annals of Oncology (2019)
Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study
Authors: N. Fazio, G. Petralia, P. Mancuso, K. Lorizzo, C. Jemos, S. Boselli, C. Porcu, F. Bertolini, M. Bellomi, F. de Braud
Journal: Journal of Clinical Oncology (2007)

15076 Background: thalidomide has been reported to have anti-angiogenic properties and therefore has been studied in several hypervascularized cancers. We evaluated the effect of thalidomide on progression-free survival (PFS) and several surrogate markers of angiogenesis in patients (pts) with advanced hepatocellular carcinoma (HCC). Methods: from June 2005 to November 2006, 19 out of the foreseen 24 HCC pts were treated with oral thalidomide 200 mg/day continuously. All of them had cytological/histological diagnosis of HCC, with no indication for curative treatment. Prior treatment was allowed. Six-month PFS was the main clinical endpoint. Perfusion parameters (Blood Flow -BF-, Blood Volume -BV-, Permeability Surface -PS-, and Mean Transit Time -MTT-) were measured with perfusion Computed Tomography (CTp). Circulating endothelial cells (CEC), progenitor cells (CEP), and apoptotic CECs, were measured by flow cytometry. Results: Eleven pts were HCV-positive and 4 HBV-positive. Eighteen had cirrhosis (80% Child-Pugh A). Five pts had extra-hepatic metastases. The maximum CLIP value was 3, in 5 pts. Six-month PFS was 41%. Constipation and somnolence were the most common G2–3 toxicities, occurring in 50% and 18% of pts, respectively. Three pts stopped treatment because of toxicity (one oedema, one neurotoxicity, and one suspect intratumoral bleeding). Baseline BF and BV of HCC were significantly higher (p&lt;.05) for the background liver in 18 evaluable pts. BF and BV remained quite stable at six months in the 7 pts free of progression, whereas they increased at the time of progression in the 9 pts with progression within 6 months. The baseline BV in the 7 pts free of progression at 6 months was significantly lower compared with that of pts progressive within 6 months (p=0.03). Seven out of 9 pts who underwent both perfusional and circulating evaluations are currently evaluable at 2 months (2 too early). BF and BV showed an inverse trend with respect to CECs in the 4 pts with PD. Pharmacokinetics and QoL evaluation is ongoing. Conclusions: thalidomide may prolong PFS in pts with advanced HCC, with manageable toxicity. CTp and CECs detection could be used to assess the antiangiogenic drug activity, but it requires further studies to be confirmed. The BV grade could be studied as a predictive factor No significant financial relationships to disclose.
PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma
Authors: Johannes M. Waldschmidt, Dagmar Wider, Stefan J. Müller, Anna Simon, Sarah Decker, Marie Follo, Justus Duyster, Ralph Wäsch, Monika Engelhardt
Journal: Blood (2016)
High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkin’s Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years
Authors: Thomas Gastinne, Gandhi Damaj, Thierry Lamy, Norbert Ifrah, Eric Deconinck, Remy Gressin, Philippe Colombat, Vincent Delwail, Christian Berthou, Jean François Rossi, Jean Luc Harousseau, Noel-Jean Milpied
Journal: Blood (2008)
Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS)
Authors: Nelli Bejanyan, Jaroslaw P. Maciejewski, Lisa Rybicki, Christine L. O'Keefe, Nolyn Nyatanga, Shawnda Tench, Mikkael A. Sekeres, Anjali S. Advani, Yogen Saunthararajah, Hien Duong, Ronald Sobecks, Matt Kalaycio, Brian J. Bolwell, Edward A. Copelan
Journal: Blood (2011)
Ethnic Differences in the Prevalence of, and Predictors for Anxiety, Depression, and Somatic Distress in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS)
Authors: Can-Lan Sun, Liton Francisco, K. Scott Baker, Stephen J. Forman, Smita Bhatia
Journal: Blood (2008)
Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure,
Authors: Thomas O'Hare, Christopher A. Eide, Lauren T. Adrian, Anupriya Agarwal, Matthew S. Zabriskie, Ryan MacKenzie, Dorian H. LaTocha, Huihong You, Jenny Luo, Steven M. Riddle, Bryan Marks, Dennis R. Koop, John Apgar, Michael W. Deininger, Brian J. Druker
Journal: Blood (2011)
Efficacy of Donor Lymphocyte Infusions in Myelodysplastic Syndromes Relapsing after Allogeneic Stem Cell Transplantation: Importance of Karyotype.
Authors: Dominik L.D. Selleslag, Friedel Nollet, Johan Billiet, Jan Van Droogenbroeck, Achiel Van Hoof, Koen Van Eygen, Melanny Hidajat, Arnold Criel
Journal: Blood (2004)
An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy
Authors: Paul Ferguson, Robert K Hills, Angela Grech, Sophie Betteridge, Lars Kjeldsen, Michael Dennis, Paresh Vyas, Alan K. Burnett, Anthony H. Goldstone, Donald Milligan, Richard E. Clark, Nigel H. Russell, Charles Craddock
Journal: Blood (2015)
Identifying Sepsis Phenotypes
Authors: Jill Moser, Matijs van Meurs, Jan G. Zijlstra
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response
Authors: Ceri E Oldreive, Anna Skowronska, Angelo Agathanggelou, Helen M Parry, Sergey Krysov, Graham K Packham, Rudzki Zbgniew, Guy Pratt, A. Malcolm R Taylor, Paul Moss, Tatjana Stankovic
Journal: Blood (2014)
Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain
Authors: Luis Felipe Casado Montero, Valentin Garcia Gutierrez, Pilar Giraldo, Manuel Perez-Encinas, Raquel de Paz, Joaquin Martinez-Lopez, Guiomar Bautista, Santiago Osorio, Maria Jose Requena, Luis Palomera, Maria Jesús Peñarrubia, Carmen Calle, Jose Angel Hernandez-Rivas, Nuria García-Ormeña, Juan Luis Steegmann
Journal: Blood (2016)
Guideline Discordance and Patient Cost Responsibility in Medicare Beneficiaries With Metastatic Breast Cancer
Authors: Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, Gabrielle B. Rocque
Journal: Journal of the National Comprehensive Cancer Network (2019)

Treatment for metastatic breast cancer (MBC) that is not concordant with the NCCN Guidelines for Breast Cancer has been associated with higher healthcare utilization and payer costs. However, a significant knowledge gap exists regarding the impact of guideline-discordant care on patient cost responsibility. This study examined this question among patients with MBC in the year postdiagnosis.This retrospective cohort study used data from the SEER-Medicare linked database from 2000 through 2013. Guideline discordance, defined by year-specific NCCN Guidelines, was assessed for first-line antineoplastic treatment and grouped into discrete categories. Patient cost responsibility (deductibles, coinsurance, copayments) in women with MBC were summed for all medical care received in the year postdiagnosis. The difference in patient cost responsibility by guideline discordance status was estimated using linear mixed-effect models.Of 3,709 patients with MBC surviving at least 1 year postdiagnosis, 17.6% (n=651) received guideline-discordant treatment. Median cost responsibility in the year postdiagnosis for patients receiving guideline-discordant treatment was $7,421 (interquartile range [IQR], $4,359-$12,983) versus $5,171 (IQR, $3,006-$8,483) for those receiving guideline-concordant care. In adjusted models, guideline-discordant treatment was significantly associated with $1,841 higher patient costs in the first year from index diagnosis date (95% CI, $1,280-$2,401) compared with guideline-concordant care. Patient cost responsibility differed by category of guideline discordance, with those receiving nonapproved bevacizumab having the highest cost responsibility (β=$3,330; 95% CI, $1,711-$4,948).Deviations from current treatment guidelines may have implications on patient healthcare cost responsibility. Additional research is needed to fully understand the mechanisms underlying how guideline deviation leads to greater costs for patients with MBC.
Incidence and Risk Factors for Vzv Infection after Allogeneic Hematopoietic Cell Transplantation in 1,045 Patients: Younger Age Less Than or Equal to 45, Occurrence of Cgvhd By NIH Consensus Criteria, and No T-Cell Depletion
Authors: Sita D. Bhella, Elizabeth Shin, Marc Poch Martell, Jieun Uhm, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Dennis Dong Hwan Kim
Journal: Blood (2015)
The Transcriptional Profile of Follicular Lymphoma Associated Regulatory T-Cells (Tregs) Is More Consistent with Tregs Having a Germinal Center Localization and the Ability to Suppress Follicular Helper T-Cells
Authors: Shannon P. Hilchey, Alexander F. Rosenberg, Stephen L. Welle, Ollivier Hyrien, Steven H. Bernstein
Journal: Blood (2012)
Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom
Authors: Stefanie Huhn, Mathias Hänel, Thomas Hielscher, Uta Bertsch, Hans Jürgen Salwender, Norma Peter, Hartmut Kirchner, Helga Bernhard, Martin Vogel, Ralf Angermund, Martin Goerner, Katja C. Weisel, Jan Duering, Igor W Blau, Niels Weinhold, Hartmut Goldschmidt
Journal: Blood (2017)